OS Therapies (OSTX): Among the Penny Stocks With Huge Upside Potential According to Analysts

OS Therapies to Attend The Jones Healthcare and Technology Innovation Conference

OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference

OS Therapies schedules Scientific Advice Meeting for OST-HER2 in Q3

OS Therapies Schedules United Kingdom’s Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma

Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Join OS Therapies’ Exclusive Live Investor Webinar and Q&A Session on February 27

OS Therapies Forms Drug Conjugates Unit, Reviews Options for Tunable ADC, Drug Conjugates Platforms

OS Therapies Is Maintained at Buy by D. Boral Capital

Os Therapies Forms Subsidiary Os Drug Conjugates and Initiates Review of Strategic Options for Its Tunable ADC & Drug Conjugates Platforms

Os Therapies Inc - in Discussions to Form Joint Ventures With ADC Companies

OS Therapies receives patent notice of allowance for OST-HER2

Sector Update: Health Care Stocks Decline Late Afternoon

Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer

BUZZ-OS Therapies rises after starting commercial production of cancer therapy

OS Therapies Says It Signed Manufacturing Deal for Lead Candidate OST-HER2

BRIEF-OS Therapies Initiates Commercial-Ready Manufacturing Of OST-HER2 To Support Anticipated Biologics Licensing Authorization (BLA) Filing

Os Therapies Initiates Commercial-Ready Manufacturing of Ost-Her2 to Support Anticipated Biologics Licensing Authorization (Bla) Filing

Os Therapies: Evaluating Strategic Options for Tunable Antibody Drug Conjugate Platform

Os Therapies Provides Corporate Update